医学研究与教育 ›› 2018, Vol. 35 ›› Issue (6): 42-47.DOI: 10.3969/j.issn.1674-490X.2018.06.009

• 临床医学 • 上一篇    下一篇

氨磺必利与利培酮治疗阴性症状为主精神分裂症疗效及安全性对照研究

崔彦龙1,2,严保平2,孙秀丽2,成玉敏2,曹志然1   

  1. 1.河北大学医学院, 河北 保定 071000;
    2. 河北省精神卫生中心, 河北 保定 071000
  • 收稿日期:2018-10-31 出版日期:2018-12-25 发布日期:2018-12-25
  • 通讯作者: 曹志然(1963—),女,河北景县人,教授,硕士生导师,主要从事免疫药理学研究。E-mail: caozhiran@163.com
  • 作者简介:崔彦龙(1985—),男,河北石家庄人,主治医师,在读硕士,主要从事临床精神病学研究。 E-mail: fooler1013@163.com
  • 基金资助:
    河北省财政厅河北省卫生计生委2017年政府资助临床医学优秀人才培养和基础课题研究计划项目

  • Received:2018-10-31 Online:2018-12-25 Published:2018-12-25

摘要: 目的 对比氨磺必利与利培酮治疗以阴性症状为主精神分裂症疗效及安全性。方法 以河北省精神卫生中心住院的阴性症状为主精神分裂症患者为研究对象,对符合入组标准且不符合排除标准的患者随机分为氨磺必利组及利培酮组,每组35例。分别于入组时、4周末、8周末进行阳性和阴性症状量表(PANSS)、阴性症状量表(SANS)、临床总体印象量表(CGI-S)、副反应量表(TESS)评定。结果 氨磺必利组完成32例,利培酮组完成31例。氨磺必利组药物剂量(665.63±167.74)mg,利培酮组药物剂量(4.32±0.98)mg。4周末和8周末时氨磺必利组PANSS阴性症状评分及SANS评分均低于利培酮组(P<0.05);两组组内比较,8周末时PANSS、SANS、CGI-S评分均较入组时评分下降,差异有统计学意义(P<0.05);两组均未出现严重不良反应,不良反应比较差异无统计学意义(56.25% vs. 67.74%,χ2=0.882,P=0.348),氨磺必利组以便秘、体重增加、震颤、口干等不良反应为主,利培酮组以震颤、静坐不能、便秘、心动过速等不良反应为主。结论 氨磺必利与利培酮均可改善阴性症状为主精神分裂症的症状,但氨磺必利改善阴性症状效果更明显。

关键词: 精神分裂症, 阴性症状, 氨磺必利, 利培酮

Abstract: Objective To compare the efficacy and safety of amisulpride and risperidone in the treatment of schizophrenia with negative symptoms.Methods Patients with schizophrenia who were hospitalized in Mental Health Center of Hebei Province were included in the study. Patients who met the inclusion criteria and did not meet the exclusion criteria were randomly assigned to the amisulpride group and the risperidone group(35 cases in each group ). Positive and negative symptom scales(PANSS), negative symptom scales(SANS), clinical overall impression scale(CGI-S), and side effects scale(TESS)were evaluated at the time of enrollment, 4 weeks, and 8 weeks. Results Thirty-two patients in the amisulpride group were examined and 31 patients in the risperidone group were determined. The dose of amisulpride group was(665.63±167.74)mg and the dose of risperidone group was(4.32±0.98)mg. PANSS negative symptom scores and SANS scores in the amisulpride group were lower than those in the risperidone group at 4 and 8 weekends(P<0.05). PANSS, SANS, and CGI-S scores were compared at 8 weeks. The scores were decreased when enrolled, and the difference was statistically significant(P<0.05). There were no serious adverse reactions in the two groups. The adverse reactions were different(56.25% vs. 67.74%, χ2=0.882, P=0.348). The amisulpride group mainly relied on adverse reactions such as secretory, weight gain, tremor, and dry mouth. Risperidone was mainly caused by adverse reactions such as tremor, sedation, constipation, and tachycardia. Conclusion Both amisulpride and risperidone can improve the efficacy of negative symptoms as schizophrenia, but amisulpride is more effective in improving negative symptoms.

Key words: schizophrenia, negative symptoms, amisulpride, risperidone

中图分类号: